Form D · Other Health Care
Nexosome Oncology Holdings, Inc.
Lexington, KY · CIK 0001894897
Offering snapshot reported Nov 22, 2021 · SEC filing
- Reported sold
- $3.65M Offering amount: $4M
- Investors reported
- 48 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 5, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 22, 2021 | Initial | $3,652,126 | No comparison | 48 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-422096
Total amount sold includes conversion of equity participation agreements.
Source: Form D, filed Nov 22, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Brian Brohman | Director |
| Matthew Dicken | Director |
| Alan Ezrin | Director |
| Todd Hembrough | Director, Executive |
| Robert Saunders | Director |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
8700 Corporate Drive Suite 403
Lexington, KY, 40503
Lexington, KY, 40503